TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Preliminary efficacy, safety and PK/PD data demonstrates favorable benefit risk profile and support future exploration of osemitamab at the recommended dose of 6mg/kg Q3W or 4mg/kg Q2W
The synergistic effects of Osemitamab and GC standard of care (SoC: antiPD-1 mAb + Oxa/5-FU) observed in our preclinical tumor models support Osemitamab in combination with SoC chemotherapy +/- Nivolumab in G/GEJ patients regardless of PD-L1 status.
Adding CLDN18.2 antibody to chemotherapy is a clinically validated approach to improve longterm outcomes for patients with high CLDN18.2 expressing tumors (proved by GLOW and SPOTLIGHT). Osemitamab (TST001) is a potential best-in-class humanized antibody with high affinity for CLDN18.2 and enhanced ADCC (antibody-dependent cellular cytotoxicity), delivering potent antitumor activities in both low and high CLDN18.2 expressing tumors. Osemitamab monotherapy has stronger tumor growth inhibition effect than the zolbetuximab (IMAB362)-analog at the same dose, regardless of CLDN18.2 expression levels. Preclinical studies showed that TST001 plus chemotherapy had better inhibitory effects on tumor growth than chemotherapy.
TST001 is a potential best-in-class antibody with higher CLDN18.2 binding affinity and lower fucose, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) activity.
Claudin-18 isoform 2 (CLDN18.2) is a member of the human claudin family of tetraspan membrane proteins that are crucial structural and functional components of tight junctions. CLDN18.2 expression is strictly limited to differentiated epithelial cells of gastric mucosa. CLDN18.2 is ectopically expressed at a significant level in multiple tumor types including gastric, esophageal, pancreatic and lung cancers, making it an attractive anti-cancer target. In G/GEJ cancer, its expression is independent from PD-L1.
TST001 is a recombinant humanized CLDN18.2 antibody that selectively binds to the extracellular loop of human Claudin18.2. In this study, we constructed a solid target radionuclide zirconium-89 (89Zr) labled-TST001 to detect the expression of in the human stomach cancer BGC823CLDN18.2 cell lines.
Claudin-18 isoform 2 (CLDN18.2) is a member of the human claudin family of tetraspan membrane proteins that are crucial structural and functional components of tight junctions4. Unlike other family members, CLDN18.2 expression is strictly limited to differentiated epithelial cells of gastric mucosa4, 5. Interestingly CLDN18.2 is ectopically expressed at a significant level in multiple tumor types including gastric, esophageal, pancreatic and lung cancers, making it an attractive anti-cancer target5. In G/GEJ cancer, its expression is independent from PD-L16.
This study investigated the prevalence of Claudin18.2 expression from surgical resections of G/GEJ adenocarcinoma at diagnosis and its correlation with PD-L1 expression in a cohort of Chinese patients.
TST001 is a recombinant humanized antibody. Here we report the TST001 in combination with CAPOX as the first line treatment of patients with G/GEJ cancer is well tolerated and encouraging anti-tumor activities have been observed.
TST001 is a recombinant humanized IgG1 antibody specifically against human Claudin18.2 (CLDN18.2) with high affinity and enhanced FcR engaging of NK cell.
This phase I clinical trial enrolls patients with advanced or metastatic solid tumors who progressed on or after standard treatments. In the dose escalation phase, patients without preselection of tumor CLDN18.2 expression were given increasing doses of TST001 intravenously every 3 weeks (Q3W) using a 3+3 design.
In normal conditions, Claudin (CLDN)18.2 is a tight junction protein with expression strictly confined to differentiated epithelial cells in gastric mucosa. CLDN18.2 has been found to be upregulated, and involved in tumor development and progression in a variety of tumor types such as gastric, pancreatic, and bile duct cancer (BTC).
Claudin18.2 (CLDN18.2), a member of tight junction protein family, is strictly limited to differentiated epithelial cells of gastric mucosa and is overexpressed in multiple tumor types, such as gastric, esophageal and pancreatic cancers.
Claudin-18 isoform 2 (CLDN18.2) is a member of the human claudin family of tetraspan membrane proteins that are crucial structural and functional components of tight junctions.
Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD).
Here we identify Gremlin1 as a ligand for fibroblast growth factor receptor 1 (FGFR1), which promotes lineage plasticity and drives castration resistance. Importantly, we generate a specific anti-Gremlin1 therapeutic antibody and demonstrate synergistic effect with androgen deprivation therapy (ADT) in CRPC.
TST004 is a humanized IgG4 anti-MASP2 antibody. Here we report the in vitro characterization of TST004, as well as in vivo pharmacokinetic (PK) and pharmacodynamic (PD) and safety profiles in cynomolgus monkeys.
TST005 is a novel bi-functional fusion protein combining a high affinity PD-L1 monoclonal antibody (mAb) in a fragment crystallizable (Fc) silenced immunoglobulin G1 (IgG1) backbone and a differentiated transforming growth factor beta (TGF‑β) trap with improved stability. This study investigated the safety, tolerability and preliminary anti-tumor activity of TST005 in solid tumors.
MSB0254 is a humanized vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody which inhibits angiogenesis induced by either VEGF-A or –C.This is a phase I study to evaluate MSB0254’s safety, tolerability and PK profiles, as well as preliminary anti-cancer activities in Chinese patients with advanced solid tumors.
Antibodies targeting PD1/PD-L1 are emerging as effective cancer immunotherapies, however, not all patients with PD-L1 expression respond to the treatment.
MSB2311 injection shows promising anti-tumor activities with favorable safety and tolerability profile in patients with advanced solid tumors and lymphoma who failed with multiple lines of prior therapies, which is worthy of further clinical studies.
MSB0254 injection demostrates anti-tumor activities with favorable safety and tolerability profile in Chinese patients with advanced tumors.
MSB2311 is a novel humanized PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.
Treatment with immune checkpoint inhibitors, including anti-PD(L)-1 antibodies, has demonstrated durable responses in patients with PD-L1 expressing tumors.
MSB2311 is a novel humanized programmed death-ligand 1 (PD-L1) antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.